Latest News
Investor Relations
Latest News
October 28, 2024 01:58 pm
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 23, 2024 07:00 am
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
October 17, 2024 07:00 am
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
October 15, 2024 07:00 am
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
October 2, 2024 07:00 am
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
September 30, 2024 07:00 am
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
August 29, 2024 07:00 am
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
August 21, 2024 07:00 am
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
August 12, 2024 04:14 pm